B. Riley assumed coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a research report report published on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $10.00 target price on the stock.
Other analysts also recently issued research reports about the company. Cantor Fitzgerald lowered their target price on Endo International from $9.00 to $7.00 and set a neutral rating on the stock in a research note on Friday, November 10th. ValuEngine downgraded Endo International from a buy rating to a hold rating in a research note on Friday, February 2nd. BidaskClub upgraded Endo International from a sell rating to a hold rating in a research note on Tuesday, December 12th. Guggenheim assumed coverage on Endo International in a research note on Tuesday, December 12th. They issued a neutral rating and a $8.50 target price on the stock. Finally, Citigroup lowered their target price on Endo International from $9.00 to $7.00 and set a neutral rating on the stock in a research note on Friday, November 10th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $10.51.
Shares of Endo International (NASDAQ:ENDP) traded up $0.41 on Wednesday, hitting $6.73. The stock had a trading volume of 4,968,900 shares, compared to its average volume of 6,097,896. Endo International has a 1 year low of $5.77 and a 1 year high of $14.45. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78. The stock has a market capitalization of $1,411.34, a P/E ratio of -0.30, a price-to-earnings-growth ratio of 2.20 and a beta of 0.29.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.